$1.26 EPS Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter

Wall Street brokerages predict that Charles River Laboratories Intl. Inc (NYSE:CRL) will announce $1.26 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Charles River Laboratories Intl.’s earnings, with estimates ranging from $1.23 to $1.29. Charles River Laboratories Intl. posted earnings of $1.21 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 4.1%. The business is expected to announce its next quarterly earnings results on Tuesday, February 13th.

According to Zacks, analysts expect that Charles River Laboratories Intl. will report full year earnings of $5.14 per share for the current year, with EPS estimates ranging from $5.10 to $5.16. For the next year, analysts expect that the firm will report earnings of $5.60 per share, with EPS estimates ranging from $5.45 to $5.86. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. The company had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. During the same quarter last year, the company earned $1.18 earnings per share. Charles River Laboratories Intl.’s quarterly revenue was up 9.0% compared to the same quarter last year.

A number of equities research analysts have commented on CRL shares. Jefferies Group raised their target price on Charles River Laboratories Intl. from $120.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 9th. Credit Suisse Group reissued a “neutral” rating and issued a $112.00 target price (up previously from $95.00) on shares of Charles River Laboratories Intl. in a report on Monday, October 16th. Zacks Investment Research raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a report on Tuesday, October 24th. Bank of America reduced their target price on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, November 10th. Finally, ValuEngine downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $112.75.

Shares of Charles River Laboratories Intl. (NYSE CRL) opened at $107.89 on Friday. Charles River Laboratories Intl. has a fifty-two week low of $77.61 and a fifty-two week high of $119.05. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. The company has a market capitalization of $5,110.00, a price-to-earnings ratio of 26.38, a price-to-earnings-growth ratio of 1.56 and a beta of 0.88.

In related news, Director Online Communications Bdirect sold 131,000 shares of Charles River Laboratories Intl. stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $0.29, for a total transaction of $37,990.00. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of Charles River Laboratories Intl. stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $0.27, for a total value of $270,000.00. In the last 90 days, insiders sold 1,195,673 shares of company stock valued at $2,914,046. Company insiders own 2.20% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CRL. YorkBridge Wealth Partners LLC increased its position in Charles River Laboratories Intl. by 445.5% during the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after purchasing an additional 891 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in Charles River Laboratories Intl. by 69.0% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after purchasing an additional 548 shares in the last quarter. Advisor Group Inc. increased its position in Charles River Laboratories Intl. by 159.4% during the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after purchasing an additional 945 shares in the last quarter. Riverhead Capital Management LLC increased its position in Charles River Laboratories Intl. by 14.7% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after purchasing an additional 247 shares in the last quarter. Finally, Zions Bancorporation purchased a new stake in Charles River Laboratories Intl. during the 3rd quarter worth about $212,000. Hedge funds and other institutional investors own 96.12% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/20/1-26-eps-expected-for-charles-river-laboratories-intl-inc-crl-this-quarter.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply